AFQLIR 40 mg inj 2 mg/0.05ml flac

7680701270013 CH-70127 S01LA05 11.99.0.

Active substances:

Afliberceptum

No images available

Details

Product number
7012701
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
afliberceptum 2 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile, ad solutionem pro 0.05 ml corresp. natrium 1.73 µg.

Articles (1)

Afqlir 40 mg/ml, Injektionslösung
Injektionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
afliberceptum
2.0 MG Substance Wirkstoff (Principe actif)
histidinum
- Substance HNIDK
histidini hydrochloridum monohydricum
- Substance HNIDK
trehalosum dihydricum
- Substance HNIDK
polysorbatum 20
- Substance HNIDK
acidum hydrochloridum
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
1.73 UG Substance HBESI

Authorization holder

Sandoz Pharmaceuticals AG

6343 Risch

Authorization information

Swissmedic authorization number
70127
Drug name
Afqlir, Injektionslösung
Galenic form
LSINJ
ATC Code
S01LA05
Authorization status
Z
Dispensation category
B
First authorization
25/09/2025
Authorization expiration date
24/09/2030
IT number
11.99.0.
Domain
Human medicine
Field of application
Exsudative (feuchte) altersbezogene Makuladegeneration (wAMD). Makulaödem infolge eines retinalen Zentralvenenverschlusses (CRVO) und retinalen Venenastverschlusses (BRVO). Diabetisches Makulaödem (DME). Behandlung von subfovealen und juxtafovealen choroidalen Neovaskularisationen infolge einer pathologischen Myopie (mCNV).

Packaging details

Description (FR)
AFQLIR 40 mg inj 2 mg/0.05ml flac
Description (DE)
AFQLIR 40 mg Inj Lös 2 mg/0.05ml Durchstf
Market launch
31/12/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data